Planned Interim Analysis of a Phase 2 Investigator-Initiated Trial of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel
Emily C. Liang(Fred Hutch Cancer Center), Jordan Gauthier(Seattle Cancer Care Alliance), Erik L. Kimble(University of Washington), David G. Maloney(Fred Hutch Cancer Center), Delaney R. Kirchmeier(Fred Hutch Cancer Center), Natalie Wuliji(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Aiko Torkelson(Fred Hutch Cancer Center), Qian Wu(Cancer Research Center), Andrew J. Portuguese(University of Washington), Aude G. Chapuis(University of Washington), Brian G. Till(University of Washington), Alexandre V. Hirayama(University of Washington), Mazyar Shadman(University of Washington), Filippo Milano(Fred Hutch Cancer Center), Lorenzo Iovino(University of Pisa), Evan W. Newell(Agency for Science, Technology and Research), Folashade Otegbeye(University Hospitals of Cleveland), Aya Albittar(University of Washington), Ryan D. Cassaday(University of Washington), Cameron J. Turtle(The University of Sydney), Abigail Chutnik(Fred Hutch Cancer Center), Nikki Pin(Fred Hutch Cancer Center), Joseph De Los Reyes(Fred Hutch Cancer Center), Jennifer J. Huang(Stanford Medicine), Sylvain Simon(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Barbara S. Pender, Tony Chour(University of Washington)
Cited by 2
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
|Blood|2017|1.1k